Provider-Based Attestation and NPI Requirements for Off-Campus HOPDs

The Consolidated Appropriations Act of 2026 requires hospitals with off-campus HOPDs to submit provider-based attestations and obtain separate NPIs by January 1, 2028. Non-compliant off-campus HOPDs will lose Medicare payment eligibility and potentially 340B drug pricing access.

State AI Legislation Update: Chatbot and Healthcare AI Laws Enacted

Oregon and Idaho enacted chatbot bills into law, while Tennessee signed a healthcare AI bill. All three contain private rights of action with statutory damages. This weekly update tracks state AI legislation affecting private-sector AI developers and deployers, including bill movements in Nebraska, Hawaii, Missouri, Massachusetts, Rhode Island, Louisiana, and South Carolina.

Healthcare Privacy Complexity Beyond HIPAA and AI Risks

WilmerHale published an analysis noting that healthcare privacy compliance has grown increasingly complex beyond traditional HIPAA frameworks, driven by evolving data security risks and expanding AI opportunities in healthcare. The article identifies meaningful compliance risks across the healthcare ecosystem but does not impose new regulatory requirements.

CMS Medicare Advantage and Part D Final Rule for Contract Year 2027

The White House released the President's FY 2027 budget request and CMS finalized policy and technical changes to Medicare Advantage, the Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly for contract year 2027. These changes affect MA organizations and Part D plan sponsors.

Private Equity Healthcare Regulatory Analysis and Trump Policy Outlook

Akin Gump Strauss Hauer & Feld LLP published a regulatory outlook analyzing the impact of Trump administration policies on private equity investments in healthcare and life sciences. The analysis covers projected Medicaid spending cuts exceeding $800 billion under the One Big Beautiful Bill Act, expired ACA subsidies, and emerging opportunities in AI-driven health technology.

CREDITGPT Trademark Extension Marked Moot

The TTAB marked extension proceeding 98956739 moot in the CREDITGPT trademark dispute between OpenAI OpCo, LLC (plaintiff) and CCP3 LLC (defendant). No substantive decision was rendered on the merits of the trademark extension request.

BI2 Technologies Trademark Appeal

BI2 Technologies, LLC filed an Ex Parte Appeal (No. 98963487) with the USPTO Trademark Trial and Appeal Board on April 6, 2026. The appeal contests a prior USPTO examining attorney decision regarding the registrability of BI2 Technologies' trademark. TTAB will review the evidence and arguments to determine whether the mark should proceed to registration.

Mesolini Glass Studio v. USPTO - Trademark Appeal Terminated

The USPTO Trademark Trial and Appeal Board issued a termination notice for Ex Parte Appeal TTAB99028377 filed by Mesolini Glass Studio. The appeal, which was filed on March 5, 2026, has been terminated. No substantive decision on the merits was rendered.

PatFounder LLC Trademark Ex Parte Appeal

The USPTO Trademark Trial and Appeal Board received Ex Parte Appeal #99091158 filed by PatFounder LLC on April 6, 2026. This appeal challenges a prior trademark examination decision and will be reviewed by the Board for affirmance, reversal, or remand.

FLOWORKS INTERNATIONAL LLC Trademark Ex Parte Appeal

FLOWORKS INTERNATIONAL LLC filed an ex parte appeal with the USPTO Trademark Trial and Appeal Board (TTAB). The appeal, designated as case TTAB #99094637, was filed on April 6, 2026. This is a routine administrative filing as part of the trademark registration process.